Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer

This phase I trial tests whether fluoxetine (prozac) works to modify the tumor immune cells before surgery in patients with colorectal cancer. Fluoxetine is a commonly used selective serotonin reuptake inhibitor (SSRI) prescribed for major depressive disorder and generalized anxiety. Giving fluoxetine may modify the immune cell composition in the tumor and its microenvironment and may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread in patients with colorectal cancer.

Trial Details

NCT ID
NCT06225011
Phase
PHASE1
Sponsor
Jonsson Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Fluoxetine
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

  • Male or female ≥ 18 years of age at visit 1
  • Previously untreated cytologically or histologically confirmed colorectal adenocarcinoma that will not need neoadjuvant therapy
  • Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply wit…
  • World Health Organization (WHO) Eastern Cooperative Oncology Group (ECOG) performance status 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →